Norvir ( DrugBank: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
265	脂肪萎縮症	4
299	嚢胞性線維症	1

265. 脂肪萎縮症

臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00426296 (ClinicalTrials.gov)	August 2006	23/1/2007	SHARE: Simple HAART With Abacavir, Reyataz, and Epivir	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks	HIV Infections;Lipodystrophy	Drug: atazanavir (Reyataz);Drug: ritonavir (Norvir)	Clinical Alliance for Research & Education - Infectious Diseases, LLC.	GlaxoSmithKline	Recruiting	18 Years	N/A	Both		Phase 4	United States
2	EUCTR2004-002740-10-DE (EUCTR)	07/11/2005	04/10/2005	A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, version 2.0 dated 13-Feb-05Revised Protocol 03, version v8.0, incorporating Protocol Amendments 03, 04 and 05 - THE REAL STUDY - RESEARCH INTO ATAZANAVIR IN LIPODYSTROPHY	A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, version 2.0 dated 13-Feb-05Revised Protocol 03, version v8.0, incorporating Protocol Amendments 03, 04 and 05 - THE REAL STUDY - RESEARCH INTO ATAZANAVIR IN LIPODYSTROPHY	HIV-infected individuals with lipodystrophy	Trade Name: Reyataz Product Name: Reyataz Product Code: BMS-232632 INN or Proposed INN: Atazanavir Other descriptive name: ATV Trade Name: Norvir Product Name: Norvir INN or Proposed INN: Ritonavir Other descriptive name: RTV	Bristol-Myers Squibb International Corporation	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 4	United Kingdom;Germany;Spain;Italy
3	EUCTR2004-002740-10-ES (EUCTR)	16/05/2005	17/05/2006	A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, version 2.0 dated 13-Feb-05Revised protocol 02 version 6.0, incorporating Amendment 03 and 04 dated 27-Oct-05. - THE REAL STUDY - RESEARCH INTO ATAZANAVIR IN LIPODYSTROPHY	A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, version 2.0 dated 13-Feb-05Revised protocol 02 version 6.0, incorporating Amendment 03 and 04 dated 27-Oct-05. - THE REAL STUDY - RESEARCH INTO ATAZANAVIR IN LIPODYSTROPHY	HIV-infected individuals with lipodystrophy	Trade Name: Reyataz Product Name: Reyataz Product Code: BMS-232632 INN or Proposed INN: Atazanavir Other descriptive name: ATV Trade Name: Norvir Product Name: Norvir INN or Proposed INN: Ritonavir Other descriptive name: RTV	Bristol-Myers Squibb International Corporation	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 4	Germany;United Kingdom;Spain;Italy
4	EUCTR2004-002740-10-GB (EUCTR)	12/05/2005	19/04/2005	A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, version 2.0 dated 13-Feb-05, andRevised Protocol 02 version 6.0, incorporating Amendment 03 and 04 dated 27-Oct-05 - THE REAL STUDY - RESEARCH INTO ATAZANAVIR IN LIPODYSTROPHY	A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, version 2.0 dated 13-Feb-05, andRevised Protocol 02 version 6.0, incorporating Amendment 03 and 04 dated 27-Oct-05 - THE REAL STUDY - RESEARCH INTO ATAZANAVIR IN LIPODYSTROPHY	HIV-infected individuals with lipodystrophy	Trade Name: Reyataz Product Name: Reyataz Product Code: BMS-232632 INN or Proposed INN: Atazanavir Other descriptive name: ATV Trade Name: Norvir Product Name: Norvir INN or Proposed INN: Ritonavir Other descriptive name: RTV	Bristol-Myers Squibb International Corporation	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 4	Spain;Germany;Italy;United Kingdom

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-001440-18-NL (EUCTR)	30/05/2018	16/01/2018	The influence of cytochrome P450 3A4 inhibitors on serum levels of Ivacaftor in cystic fibrosis patients and healthy subjects.	Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controls - IACI	cystic fibrosis and healthy subjects;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Ivacaftor Trade Name: claritromycin 500mg film coated tablets Product Name: Claritromycin Trade Name: Azithromycin 500 mg film-coated tablet Product Name: azithromycin Trade Name: Norvir 100 mg film-coated tablets Product Name: Norvir	university medical center utrecht	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 4	Netherlands